Medical Group

Annals of Antivirals and Antiretrovirals  Open Access


    Recent articles to be released shortly in Volume-3
    mendeley

    Castalagin: Some aspects of the mode of Anti-Herpes Virus Activity CrossMark

    DOI Logo 10.17352/aaa.000004

    Published On: February 15, 2018 | Pages: 004 - 007

    Author(s): N Vilhelmova-Ilieva, D Deffieux, S Quideau, AS Galabov*
    Castalagin, a nonahydroxytriphenoyl-bearing C-glucosidic ellagitannin, manifested a marked virucidal effect on HSV-1. ...
    Abstract View Full Article View Get Citation
    mendeley

    Thiolutin Derivatives as inhibitor of RNA-Dependent RNA Polymerase (RdRP) of Hepatitis C Virus: An In-silico Approach CrossMark

    DOI Logo 10.17352/aaa.000003

    Published On: January 17, 2018 | Pages: 001 - 003

    Author(s): Muhammad Imran Qadir*, Asma Munawar, Syed Bilal Hussain
    Docking study of few Thiolutin derivatives, which originally act as Hepatitis C Virus RNA Dependent RNA Polymerase (RdRP) inhibitor, was performed by using AutoDock Vina. The docking studies reveal that thiolutin interacted with Hepatitis C Virus RNA Dependent RNA Polymerase through hydrogen bonding as well as hydrophobic interactions. Its binding energy after modific ...
    Abstract View Full Article View Get Citation
    mendeley

    Molecular Docking studies on possible Neuraminidase Inhibitors of Influenza Virus CrossMark

    DOI Logo 10.17352/aaa.000002

    Published On: October 10, 2017 | Pages: 005 - 007

    Author(s): Jawaria Khan*, Ardas Masood, Asma Noor, Anam Munir and Muhammad Imran Qadir
    Influenza generally known as flu is due to viruses that contaminate the respiratory region. It can result in light to cruel sickness, and may cause death. The influenza pandemic of 1918-1919 took life of a lot more people than the World War 1. Peramivir that inhibits the purpose of the viral neuraminidase protein of influenza virus, therefore stopping the virus from r ...
    Abstract View Full Article View Get Citation
    mendeley

    Lack of Difference between the Reduced Dose and Full-Dose of Antiretroviral Therapy in Terms of the Decrease in Immune Activation CrossMark

    DOI Logo 10.17352/aaa.000001

    Published On: January 28, 2017 | Pages: 001 - 004

    Author(s): Nicolè S*, Cucchetto G, Lanzafame M, Rigo F, Lattuada E, Concia E and Vento S
    Virological and immunological effectiveness of reduced doses of antiretrovirals has been shown in two randomized trials and smaller studies. We have now evaluated immune activation in patients on reduced doses of antiretroviral therapy (ART) using HLA-DR+CD8+ lymphocytes as a marker of activation. ...
    Abstract View Full Article View Get Citation

     

    Global Views

    Case Reports

    Peertechz Tweets

    Pinterest on AAA